ASTS
AST SpaceMobile, Inc.
ASTS offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
NICE
NICE Ltd.
NICE has the edge over ASTS overall, supported by stronger valuation and lower modeled downside.
ASTS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
ASTS's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
NICE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
NICE's revenue, profitability, cash flow and balance sheet are all currently healthy.
ASTS PE Valuation
ASTS has no meaningful PE right now: it lost money over the past year.
NICE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 14x | $94.12 | — |
| Cheap | 17x | $116 | +23% |
| Fair | 49x | $341 | +263% |
| Expensive | 76x | $522 | +454% |
Historical ranges are pointers, not guarantees.
NICE's PE is in its cheap range at 14x.
ASTS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ASTS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
NICE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for NICE, with profitability holding steady.
ASTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.15 | -$0.91 |
| Q2 2026 | -$2.16 | -$0.27 |
| Q1 2026 | -$1.80 | +$0.19 |
| Q4 2025 | -$1.34 | +$0.61 |
| Q3 2025 | -$1.24 | +$0.88 |
| Q2 2025 | -$1.89 | -$0.64 |
| Q1 2025 | -$1.99 | -$1.01 |
| Q4 2022 | -$0.58 | -$0.21 |
ASTS is still losing money, but far less than before: $2.15 per share over the past year, against $5.76 at its worst in mid-2021.
NICE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $6.90 | -18% |
| Q1 2026 | $8.43 | +18% |
| Q4 2025 | $9.67 | +43% |
| Q3 2025 | $8.80 | +36% |
| Q2 2025 | $8.37 | +40% |
| Q1 2025 | $7.17 | +29% |
| Q4 2024 | $6.76 | +33% |
| Q3 2024 | $6.46 | +31% |
NICE has the edge over ASTS on earnings quality, reporting a profit while its opponent remains loss making.
ASTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42.3M | +187% |
| Q2 2026 | $31.5M | +2627% |
| Q1 2026 | $14.7M | +1952% |
| Q4 2025 | $54.3M | +2731% |
| Q3 2025 | $14.7M | +1240% |
| Q2 2025 | $1.2M | +28% |
| Q1 2025 | $718K | +44% |
| Q3 2022 | $4.2M | +70% |
ASTS's revenue has grown year over year for 11 quarters in a row: $42M last quarter, up 187% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -415% | +694 points |
| Q2 2026 | -948% | +10744 points |
| Q1 2026 | -1686% | +7083 points |
| Q4 2025 | -175% | +2446 points |
| Q3 2025 | -1109% | +4850 points |
| Q2 2025 | -11692% | -4693 points |
| Q1 2025 | -8769% | +2331 points |
| Q4 2024 | -2621% | N/A |
ASTS's operating margin was −415% last quarter, up 694 points from the same quarter a year ago.
NICE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $795.7M | +9.5% |
| Q1 2026 | $766.5M | +9.5% |
| Q4 2025 | $786.5M | +9% |
| Q3 2025 | $732M | +6.1% |
| Q2 2025 | $726.7M | +9.4% |
| Q1 2025 | $700.2M | +6.2% |
| Q4 2024 | $721.6M | +16% |
| Q3 2024 | $690M | +15% |
NICE's revenue has grown year over year every quarter since late 2020: $796M last quarter, up 9.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 14% | -8.3 points |
| Q1 2026 | 16% | -4.7 points |
| Q4 2025 | 22% | +1 points |
| Q3 2025 | 22% | +1.5 points |
| Q2 2025 | 22% | +2.7 points |
| Q1 2025 | 21% | +2.7 points |
| Q4 2024 | 21% | +1.7 points |
| Q3 2024 | 20% | +1.6 points |
NICE has the edge over ASTS on profitability, with a higher operating margin.
ASTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$464.2M | -$161.4M |
| Q2 2026 | -$694.8M | -$341.1M |
| Q1 2026 | -$309.7M | -$160.7M |
| Q4 2025 | -$330.7M | -$220.3M |
| Q3 2025 | -$302.9M | -$239.1M |
| Q2 2025 | -$353.6M | -$315.3M |
| Q1 2025 | -$149M | -$61.3M |
| Q4 2024 | -$110.5M | -$63.2M |
ASTS has burned cash in almost every quarter: −$1.8B over the past year, against −$916M the year before.
NICE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $117.3M | +204% |
| Q1 2026 | $169.4M | -36% |
| Q4 2025 | $156M | -31% |
| Q3 2025 | $163.6M | +24% |
| Q2 2025 | $38.6M | -74% |
| Q1 2025 | $264.6M | +16% |
| Q4 2024 | $225.1M | +40% |
| Q3 2024 | $131.7M | +28% |
NICE has the edge over ASTS on cash generation, producing positive trailing cash flow while its opponent burns cash.
ASTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +1.1M shares |
| 1 year | +10% | +27.3M shares |
| 3 years | +235% | +211M shares |
| 5 years | +480% | +248M shares |
| Available history | +944% | +271M shares |
ASTS has 300M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
NICE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2% | -1.2M shares |
| 1 year | -6% | -3.8M shares |
| 3 years | -11% | -7M shares |
| 5 years | -11% | -7.1M shares |
| Available history | -8.7% | -5.7M shares |
NICE has the edge over ASTS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $60.8M |
| Q1 2026 | $252.6M |
| Q4 2025 | $165.2M |
| Q3 2025 | $40.6M |
| Q2 2025 | $30.8M |
| Q1 2025 | $252.3M |
| Q4 2024 | $95.2M |
| Q3 2024 | $86.4M |
NICE spent $519M buying back its own shares over the past year, up 12% from the year before.
ASTS Net Leverage
ASTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NICE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | -0.2x | Net Cash |
| Q4 2025 | -0.2x | Net Cash |
| Q3 2025 | -0.4x | Net Cash |
| Q2 2025 | 0.0x | Very low |
| Q1 2025 | 0.1x | Very low |
| Q4 2024 | 0.1x | Very low |
| Q3 2024 | -0.1x | Net Cash |
NICE has more cash than debt.
ASTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 11.9 | Oversold |
ASTS's weekly RSI is 34 (neutral) and its Stochastic is 12 (oversold).
NICE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.9 | Neutral |
| Stochastic | 24.3 | Neutral |
NICE's weekly RSI is 43 (neutral) and its Stochastic is 24 (neutral).
ASTS PE vs Technology Sector
ASTS has no meaningful PE right now: it lost money over the past year.
NICE PE vs Technology Sector
| Metric | NICE | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 28x | 51% below |
| PE % | 13 | 35 | 22 pts below |
NICE is trading at 14x earnings, a 51% discount to the Technology sector's median of 28x.
ASTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.9 | 23% below |
| 20 week MA | $57.1 | 40% below |
| 50 week MA | $75.5 | 54% below |
| 100 week MA | $57.8 | 40% below |
| 200 week MA | $33.6 | 2.8% above |
ASTS has the edge over NICE on trend strength, trading above more of its moving averages.
NICE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $110.2 | 15% below |
| 20 week MA | $104.5 | 9.9% below |
| 50 week MA | $105.3 | 11% below |
| 100 week MA | $128.5 | 27% below |
| 200 week MA | $162.8 | 42% below |
NICE is in a downtrend: it's below all five of its weekly moving averages, and 42% below its 200-week average.
ASTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.87 | $13.4 | +36% |
| 2021 | $13.4 | $8.71 | -35% |
| 2022 | $8.71 | $3.97 | -54% |
| 2023 | $3.97 | $6.03 | +52% |
| 2024 | $6.03 | $22.9 | +280% |
| 2025 | $22.9 | $72.0 | +214% |
| 2026 YTD | $72.0 | $34.5 | -52% |
ASTS's yearly returns have swung widely, from +280% in 2024 to −54% in 2022. It's down 52% so far in 2026.
NICE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $156.3 | $279.8 | +79% |
| 2021 | $279.8 | $306.4 | +9.5% |
| 2022 | $306.4 | $194.7 | -36% |
| 2023 | $194.7 | $199.5 | +2.5% |
| 2024 | $199.5 | $173.5 | -13% |
| 2025 | $173.5 | $112.7 | -35% |
| 2026 YTD | $112.7 | $94.1 | -16% |
NICE has the edge over ASTS on returns for 2026, with the stronger performance.